Profile data is unavailable for this security.
About the company
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
- Revenue in USD (TTM)0.00
- Net income in USD-10.90m
- Incorporated1996
- Employees3.00
- LocationOragenics Inc9015 TOWN CENTER PARKWAY, SUITE 143LAKEWOOD RANCH 34202United StatesUSA
- Phone+1 (813) 286-7900
- Fax+1 (813) 286-7904
- Websitehttps://www.oragenics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Propanc Biopharma Inc | 0.00 | -67.00m | 3.06m | 1.00 | -- | 0.2485 | -- | -- | -13.54 | -13.54 | 0.00 | 0.851 | 0.00 | -- | -- | 0.00 | -869.88 | -- | -1,782.95 | -- | -- | -- | -- | -- | -- | -74.43 | 0.0492 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Hcw Biologics Inc | 422.03k | -22.21m | 3.11m | 36.00 | -- | -- | -- | 7.37 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 3.27m | 5.00 | -- | 0.1484 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| Oragenics Inc | 0.00 | -10.90m | 3.50m | 3.00 | -- | 0.3526 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -8.99m | 3.55m | 3.00 | -- | -- | -- | -- | -0.1302 | -0.1302 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -129.27 | -96.94 | -145.04 | -116.42 | -- | -- | -- | -- | -- | -- | 34.30 | -- | -- | -- | 67.91 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 3.56m | 17.00 | -- | 0.3874 | -- | 1.06 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.62m | 21.00 | -- | -- | -- | 32.28 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.68m | 4.00 | -- | 0.2112 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -9.17m | 3.82m | 4.00 | -- | 0.7425 | -- | -- | -8.54 | -8.54 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -151.72 | -158.12 | -291.07 | -208.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.26 | -- | -- | -- |
| PMGC Holdings Inc | 285.95k | -4.48m | 3.87m | 2.00 | -- | 0.0261 | -- | 13.52 | -57.57 | -129.01 | 3.93 | 45.64 | 0.0219 | 0.373 | 1.98 | 142,975.00 | -34.29 | -- | -48.32 | -- | 27.29 | -- | -1,567.42 | -- | 1.77 | -32.16 | 0.2734 | -- | -- | -- | -142.45 | -- | -- | -- |
| Weed Inc | 0.00 | -755.25k | 3.87m | 2.00 | -- | -- | -- | -- | -0.0058 | -0.0058 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -133.78 | -117.17 | -- | -371.94 | -- | -- | -- | -- | -- | -22.55 | -- | -- | -- | -- | -1,518.25 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.89m | 3.00 | -- | 0.5554 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.02m | 3.00 | -- | 0.1753 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Oragenics Inc's reporting currency: US Dollar USD
5.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 112.71k | 2.70% |
| Sabby Management LLCas of 31 Dec 2025 | 61.74k | 1.48% |
| XTX Markets LLCas of 31 Dec 2025 | 33.75k | 0.81% |
| Tower Research Capital LLCas of 31 Dec 2025 | 4.55k | 0.11% |
| UBS Securities LLCas of 31 Dec 2025 | 2.39k | 0.06% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 703.00 | 0.02% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 138.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 36.00 | 0.00% |
| Harbour Investments, Inc.as of 31 Dec 2025 | 34.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2025 | 34.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
